Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
By N. Masuda, Soo-Jung Lee, S. Ohtani, Y. Im, Eun-Sook Lee, I. Yokota, K. Kuroi, S. Im, Byeong-Woo Park, Sung-Bae Kim and 11 more. New England Journal of Medicine, 2017
1,559 citations recorded by the source corpus.
Subfields: Cancer Research, Dermatology, Oncology
View Paper: https://www.semanticscholar.org/paper/fe170d047badd6dd61aa23e080e9206ff8f84ce7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
Citations in the corpus
- Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline (2021, methodology): “In this context, a number of recent trials have focused on using a lack of response to neoadjuvant therapy to identify patients who have a worse prognosis and could therefore benefit from additional adjuvant treatment.(9,10)”
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018, background): “At this juncture, there are no published data that additional therapy—beyond ‘standard’ treatment—reduces recurrence risk in women with residual disease [42].”
- Breast Cancer Treatment. (2021, neutral): “42 Other Treatments.”
- Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis (2020, neutral): “Conversely, there are a number of studies exploring additional adjuvant therapies for patients with TNBC with residual disease following neoadjuvant chemotherapy, and the use of adjuvant capecitabine for such patients has become a favored approach based on the improved overall survival results obser”